HitHunter cAmp assays are homogeneous, non-radioactive, cell-based assays used to screen for G-protein coupled receptor (GPCR) activation in a microplate-based format
GE Healthcare and DiscoveRx have entered into an exclusive distribution agreement for all HitHunter cAmp enzyme fragment complementation (EFC)-based assays, designed for high throughput, non-radioactive screening of compounds in drug discovery.
"We are very pleased to announce the expansion of our agreement with DiscoveRx, which grants GE Healthcare exclusive global distribution rights to HitHunter cAmp assays and provides our customers with more options for cutting edge, high throughput screening technology".
"We are already known for our SPA screening products; adding the DiscoveRx portfolio allows us to offer a more comprehensive suite of screening technologies to our customers, combined with the high quality and service they have come to expect," says Ger Brophy, general manager of discovery sciences, at GE Healthcare.
The agreement not only grants GE Healthcare global exclusivity for DiscoveRx's cAmp assays, it also expands distribution of the company's portfolio of kinase assays, with exclusive distribution in the Asia Pacific region.
HitHunter cAmp assays are homogeneous, non-radioactive, cell-based assays used to screen for G-protein coupled receptor (GPCR) activation in a microplate-based format.
GPCRs represent a large class of membrane proteins that play an important role in cell signaling pathways and are important targets for drug discovery.
"DiscoveRx's HitHunter GPCR and kinase products are well accepted by drug discovery customers".
"We are tremendously excited about this important step forward, which broadens the global access of our HitHunter products through a premier supplier of life science research tools," says Pyare Khanna, CEO of DiscoveRx.
